941710-30-1

Basic information

• Product Name: 7-BroMochroMan
• Synonyms: 7-BroMochroMan;7-bromo-3,4-dihydro-2H-chromene;2H-1-Benzopyran, 7-bromo-3,4-dihydro-
• CAS NO: 941710-30-1
• Molecular Formula: C9H9BrO
• Molecular Weight: 213.07116
• Mol File: 941710-30-1.mol

Chemical Properties

• Boiling Point: 263.3±29.0 °C(Predicted)
• Appearance: /
• Density: 1.484±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 7-BroMochroMan(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BroMochroMan(941710-30-1)
• EPA Substance Registry System: 7-BroMochroMan(941710-30-1)

Safety Data

• Hazardous Substances Data: 941710-30-1(Hazardous Substances Data)

Usage

Uses

Used in Research Applications:
7-BroMochroMan is used as a research tool for investigating the mechanisms of cholesterol trafficking within cells. It disrupts the formation of lipid rafts, which are essential for cellular processes such as signal transduction, membrane transport, and protein trafficking.
Used in Cellular Physiology Studies:
7-BroMochroMan is used as a modulator of cellular cholesterol metabolism to study its impact on membrane organization and functions. It inhibits the intracellular transport of cholesterol, affecting its distribution and potentially influencing cellular homeostasis.
Used in Disease Research:
7-BroMochroMan is used in disease research to explore the role of cholesterol in cellular physiology and its association with various diseases. Its unique properties make it a valuable tool for investigating the underlying mechanisms and potential therapeutic targets related to cholesterol metabolism disorders.

Upstream product

• 1435-52-5 2,5-dibromofluorobenzene 
• 1037206-46-4 1,4-dibromo-2-(3-bromopropanoxyl)benzene 
• 18442-22-3 7-Bromo-2,3-dihydro-4H-chromen-4-one 

Relevant articles and documents

SUBSTITUTED TRICYCLIC COMPOUNDS

Disclosed are compounds of the general formula (I), its tautomeric form, its stereoisomer, its pharmaceutically acceptable salt, its polymorph, or solvate thereof, wherein, ring A, ring B, R1 to R4, and n are as defined herein, for use as SOS1 inhibitors in the treatment of proliferative, infectious and RASopathy diseases or disorders. Also disclosed are methods of synthesizing the compound of formula I, pharmaceutical compositions containing the compound of formula I, method of treatment of proliferative, infectious and RASopathy diseases or disorder, for example, a cancer, by administering the said compound and combinations of the compound of formula I with other active ingredients.

Novel Inhibitors of Staphyloxanthin Virulence Factor in Comparison with Linezolid and Vancomycin versus Methicillin-Resistant, Linezolid-Resistant, and Vancomycin-Intermediate Staphylococcus aureus Infections in Vivo

Our previous work (Wang et al. J. Med. Chem. 2016, 59, 4831-4848) revealed that effective benzocycloalkane-derived staphyloxanthin inhibitors against methicillin-resistant Staphylococcus aureus (S. aureus) infections were accompanied by poor water solubility and high hERG inhibition and dosages (preadministration). In this study, 92 chroman and coumaran derivatives as novel inhibitors have been addressed for overcoming deficiencies above. Derivatives 69 and 105 displayed excellent pigment inhibitory activities and low hERG inhibition, along with improvement of solubility by salt type selection. The broad and significantly potent antibacterial spectra of 69 and 105 were displayed first with normal administration in the livers and hearts in mice against pigmented S. aureus Newman, Mu50 (vancomycin-intermediate S. aureus), and NRS271 (linezolid-resistant S. aureus), compared with linezolid and vancomycin. In summary, both 69 and 105 have the potential to be developed as good antibacterial candidates targeting virulence factors.

MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS

The present invention is directed to morpholine carboxamide compounds which are antagonists of prokineticin receptors, in particular antagonists of prokineticin 2 receptors, and which are useful in the treatment or prevention of neurological and psychiatr